EIF2AK2 and adenocarcinoma: We further explored the combination of PKR and p-AMPK expression in NSCLC patients and observed that p-AMPK promotes cancer cell survival in adenocarcinoma patients with high PKR expression and inhibits cancer cell growth in adenocarcinoma patients with low PKR levels.